Semin Thromb Hemost 2012; 38(01): 47-54
DOI: 10.1055/s-0031-1300951
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Thrombotic Microangiopathies, Thrombotic Thrombocytopenic Purpura, and ADAMTS-13

Kent Chapman
1   Department of Haematology, Hunter Area Pathology Service, John Hunter Hospital, Newcastle, NSW, Australia
,
Michael Seldon
2   Calvary Mater Hospital, Newcastle, NSW, Australia
,
Ross Richards
3   Charles Sturt University, Wagga Wagga, NSW, Australia
› Author Affiliations
Further Information

Publication History

Publication Date:
07 February 2012 (online)

Abstract

Thrombotic microangiopathy (TMA) is a term used to describe a group of disorders characterized by hemolytic anemia (with prominent red blood cell fragmentation), thrombocytopenia, and thrombosis in the microvasculature. It may be used when describing patients with thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome, atypical hemolytic uremic syndrome, as well as a myriad of other disorders in which the TMA may be secondary to another disease or disorder. While limited information exists as to the exact cause of microthrombosis in many TMA, recent advances have been made in the understanding of TTP and its pathophysiology. This progress can be attributed to discovery of the von Willebrand factor cleaving protease ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), whose absence in TTP has given the disorder a distinct molecular identity. The discovery of this metalloprotease has prompted a significant amount of research relating to its role in TTP as well as its general function in hemostasis. The exact mechanisms by which this metalloprotease achieves its role are slowly being understood and these now provide other avenues by which TMA may occur.

 
  • References

  • 1 Lichtman LA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT. Williams Hematology. 7th ed. Sydney: : McGraw-Hill Medical; ; 2006
  • 2 Tsai HM. The molecular biology of thrombotic microangiopathy. Kidney Int 2006; 70 (1) 16-23
  • 3 Lämmle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost 2005; 3 (8) 1663-1675
  • 4 George JN. Diagnosis of thrombotic thrombocytopaenia purpura – haemolytic uraemic syndrome in adults. 2010, Available at: www.uptodate.com/contents/diagnosis-of-thrombotic-thrombo-cytopenic-purpura-hemolytic-uremic-syndromeinadults?source=search_result&search=thombotic+thombocytopaenia+purpura&selectedTitle=1%7E150 . Accessed October 12, 2010
  • 5 George JN. The role of ADAMTS13 in the pathogenesis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clin Adv Hematol Oncol 2005; 3 (8) 627-632
  • 6 Desch K, Motto D. Is there a shared pathophysiology for thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome?. J Am Soc Nephrol 2007; 18 (9) 2457-2460
  • 7 Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87 (10) 4235-4244
  • 8 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87 (10) 4223-4234
  • 9 Franchini M, Montagnana M, Targher G, Lippi G. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases. Semin Thromb Hemost 2007; 33 (8) 787-797
  • 10 Zhou Z, Nguyen TC, Guchhait P, Dong JF. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Thromb Hemost 2010; 36 (1) 71-81
  • 11 Favaloro EJ. Hemolytic uremic syndrome. Preface. Semin Thromb Hemost 2010; 36 (6) 573-574
  • 12 Karpman D, Sartz L, Johnson S. Pathophysiology of typical hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36 (6) 575-585
  • 13 Just S. Methodologies and clinical utility of ADAMTS-13 activity testing. Semin Thromb Hemost 2010; 36 (1) 82-90
  • 14 Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hithero undescribed disease. Proc N Y Pathol Soc. 1924; 24: 21-24
  • 15 Baehr G, Kelmerer P, Schifrin A. Acute febrile anemia and thrombocytopenic purpura with diffuse platelet thrombosis of capillaries and arterioles. Tr A Am Physicians 1936; 51: 43
  • 16 Singer K, Bornstein FP, Wile SA. Thrombotic thrombocytopenic purpura; hemorrhagic diathesis with generalized platelet thromboses. Blood 1947; 2 (6) 542-554
  • 17 Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966; 45: 139-160
  • 18 Moake JL, Rudy CK, Troll JH , et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307 (23) 1432-1435
  • 19 Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986; 78 (6) 1456-1461
  • 20 Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 1988; 71 (5) 1366-1374
  • 21 Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98 (6) 1662-1666
  • 22 Levy GG, Nichols WC, Lian EC , et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413 (6855) 488-494
  • 23 Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001; 276 (44) 41059-41063
  • 24 Kokame K, Matsumoto M, Soejima K , et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A 2002; 99 (18) 11902-11907
  • 25 Lotta LA, Garagiola I, Palla R, Cairo A, Peyvandi F. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat 2010; 31 (1) 11-19
  • 26 Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339 (22) 1585-1594
  • 27 Sheiflinger F, Knobl P, Trattner B , et al. Non-neutralising IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003; 102 (9) 3241-3243
  • 28 Key N, Makris M, O’shaunessy D, Lillicrap D. . Practical Hemostasis and Thrombosis. 2nd ed. Singapore: : Wiley-Blackwell; ; 2009
  • 29 De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. Blood 2009; 113 (21) 5049-5057
  • 30 Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424
  • 31 McGrath RT, McRae E, Smith OP, O’Donnell JS. Platelet von Willebrand factor—structure, function and biological importance. Br J Haematol 2010; 148 (6) 834-843
  • 32 Sporn LA, Marder VJ, Wagner DD. von Willebrand factor released from Weibel-Palade bodies binds more avidly to extracellular matrix than that secreted constitutively. Blood 1987; 69 (5) 1531-1534
  • 33 Arya M, Anvari B, Romo GM , et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood 2002; 99 (11) 3971-3977
  • 34 Tsai HM. Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura. Kidney Int Suppl 2009; 112 (112) S11-S14
  • 35 Uchida T, Wada H, Mizutani M , et al; Research Project on Genetics of Thrombosis. Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura. Blood 2004; 104 (7) 2081-2083
  • 36 Pimanda JE, Maekawa A, Wind T, Paxton J, Chesterman CN, Hogg PJ. Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13. Blood 2004; 103 (2) 627-629
  • 37 Zhou Z, Nguyen TC, Guchhait P, Dong JF. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Thromb Hemost 2010; 36 (1) 71-81
  • 38 Zanardelli S, Crawley JTB, Chion CK, Lam JK, Preston RJS, Lane DA. ADAMTS13 substrate recognition of von Willebrand factor A2 domain. J Biol Chem 2006; 281 (3) 1555-1563
  • 39 Vomund AN, Majerus EM. ADAMTS13 bound to endothelial cells exhibits enhanced cleavage of von Willebrand factor. J Biol Chem 2009; 284 (45) 30925-30932
  • 40 Reiter RA, Knöbl P, Varadi K, Turecek PL. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood 2003; 101 (3) 946-948
  • 41 Lippi G, Franchini M, Targher G, Poli G, Guidi GC. The significance of evaluating conventional inflammatory markers in Von Willebrand factor measurement. Clin Chim Acta 2007; 381 (2) 167-170
  • 42 Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98 (9) 2730-2735
  • 43 Furlan M, Robles R, Morselli B, Sandoz P, Lämmle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999; 81 (1) 8-13
  • 44 Barbot J, Costa E, Guerra M , et al. Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease. Br J Haematol 2001; 113 (3) 649-651
  • 45 Tandon NN, Rock G, Jamieson GA. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol 1994; 88 (4) 816-825
  • 46 Schultz DR, Arnold PI, Jy W , et al. Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders: identification of an 85 kD form of CD36 as a target antigen. Br J Haematol 1998; 103 (3) 849-857
  • 47 Rock G, Chauhan K, Jamieson GA, Tandon NN. Anti-CD36 antibodies in patients with lupus anticoagulant and thrombotic complications. Br J Haematol 1994; 88 (4) 878-880
  • 48 Rock GA, Clark WF. Mechanism of microthrombosis in HUS. Kidney Int Suppl 2009; 75 (112) S15-S16
  • 49 Nolasco LH, Turner NA, Bernardo A , et al. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood 2005; 106 (13) 4199-4209
  • 50 Morishita K, Wakamoto S, Miyazaki T , et al. Life-threatening adverse reaction followed by thrombocytopenia after passive transfusion of fresh frozen plasma containing anti-CD36 (Naka) isoantibody. Transfusion 2005; 45: 803-806
  • 51 Wakamoto S, Fujihara M, Urushibara N , et al. Heterogeneity of platelet responsiveness to anti-CD36 in plasma associated with adverse transfusion reactions. Vox Sang 2005; 88 (1) 41-51
  • 52 Tomiyama Y, Kunicki TJ, Zipf TF, Ford SB, Aster RH. Response of human platelets to activating monoclonal antibodies: importance of Fc gamma RII (CD32) phenotype and level of expression. Blood 1992; 80 (9) 2261-2268
  • 53 George JN. ADAMTS13: what it does, how it works, and why it’s important. Transfusion 2009; 49 (2) 196-198
  • 54 Crawley JT, Lam JK, Rance JB, Mollica LR, O’Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005; 105 (3) 1085-1093
  • 55 Feys HB, Vandeputte N, Palla R , et al. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8 (9) 2053-2062